What are the side effects of zanidatamab-hrii for injection - Ziihera?

Zenidatamab-hrii for injection (zanidatamab-hrii)-Ziihera is suitable as a new type of targeted therapy. Although it has shown good efficacy in the treatment of HER2-positive biliary tract cancer, it is also accompanied by some adverse reactions. According to data from clinical trials and post-marketing surveillance, the incidence of common adverse reactions is ≥20%, mainly including diarrhea, infusion-related reactions, abdominal pain and fatigue.

Diarrhea isone of the most common side effects of Ziihera use. This type of diarrhea may affect the patient's quality of life and lead to dehydration and electrolyte imbalance, so patients' diet and fluid intake need to be closely monitored while using this drug, and appropriate supportive care is provided.

Infusion-related reactions are also common side effectsZiihera. This type of reaction usually occurs at the beginning or during the infusion of the drug, and symptoms may include fever, chills, rash, shortness of breath, etc. Medical personnel should perform appropriate monitoring when infusing this drug so that these reactions can be recognized and addressed promptly to ensure patient safety.

Abdominal pain, as another adverse reaction, may be related to the mechanism of action of the drug. Patients may feel significant discomfort during treatment, affecting their diet and daily activities, so pain management needs to be carried out on a case-by-case basis.

In addition, fatigue is also a common problem faced by many patients undergoing cancer treatment.The use of Ziihera may also cause patients to feel extreme fatigue. This fatigue may be related to factors such as the side effects of the drugs themselves, the progression of the cancer, and other combined therapies. Patients should be informed of the possibility of fatigue and given necessary suggestions to help them arrange their work and rest reasonably and improve their quality of life.

It is worth noting thatZiihera also warns about embryotoxicity, which means that pregnant women may face a higher risk when using the drug. Therefore, female patients should undergo a pregnancy test before starting treatment and use effective contraceptive measures.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae5d9425-fae5-4541-a158-150998343348##